Steven Prestrelski - Jan 31, 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Scientific Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 03:12 PM
Previous filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +150K +26.33% $0.00 720K Jan 31, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.